Helperby Therapeutics Ltd
Helperby Therapeutics is a clinical-stage biopharmaceutical company based in London, UK, dedicated to developing treatments for WHO Critical and High Priority pathogens. They focus on creating novel combination therapies of approved drugs to combat antimicrobial resistance (AMR), aiming to provide cost-effective solutions worldwide. Their approach involves synergistic combinations of approved antibiotics to treat resistant bacterial infections, reduce side effects, and prevent the emergence of resistance, thereby ensuring the continued efficacy of antibiotics into the future.
Industries
Nr. of Employees
small (1-50)
Helperby Therapeutics Ltd
66 Lincoln's Inn Fields London WC2A 3LH, United Kingdom
Patents
Use of pyrroloquinoline compounds to kill clinically latent microorganisms
US-10493071-B2
View Details
Use of pyrroloquinoline compounds to kill clinically latent microorganisms
US-10493071-B2
View DetailsProducts
Lead combination therapy for resistant infections (clinical-stage)
A clinical-stage combination of approved anti-infective agents developed to treat highly resistant bacterial infections; confirmed activity in Phase I human studies.
Combination product portfolio for multiple infection types
Early-stage portfolio of combination therapies targeting complicated urinary tract infections, skin and soft tissue infections, hospital-acquired/ventilator-associated pneumonia and bloodstream infections.
Lead combination therapy for resistant infections (clinical-stage)
A clinical-stage combination of approved anti-infective agents developed to treat highly resistant bacterial infections; confirmed activity in Phase I human studies.
Combination product portfolio for multiple infection types
Early-stage portfolio of combination therapies targeting complicated urinary tract infections, skin and soft tissue infections, hospital-acquired/ventilator-associated pneumonia and bloodstream infections.
Services
Granting licenses for the use of developed antibiotic combination regimens to pharmaceutical partners for manufacture and commercialization.
Provision of R&D and development support on behalf of or jointly with partners, including pre-clinical testing, formulation planning and clinical development coordination.
Sourcing and engaging manufacturing and commercial partners, particularly for injectable hospital-based therapies and selected geographic territories.
Granting licenses for the use of developed antibiotic combination regimens to pharmaceutical partners for manufacture and commercialization.
Provision of R&D and development support on behalf of or jointly with partners, including pre-clinical testing, formulation planning and clinical development coordination.
Sourcing and engaging manufacturing and commercial partners, particularly for injectable hospital-based therapies and selected geographic territories.
Expertise Areas
- Antibiotic combination therapy development
- Clinical trial design for anti-infectives
- Preclinical microbiology and in vitro synergy testing
- Regulatory strategy for reformulated/combination products (505(b)-type pathways)
Key Technologies
- Antimicrobial combination therapy
- In vitro microbiology assays
- Synergy testing for antibiotics
- Phase I and Phase III clinical protocols
News & Updates
Confirmed in Ph I human studies
Helperby’s lead product has confirmed efficacy in Phase I human studies.
Confirmed in Ph I human studies
Helperby’s lead product has confirmed efficacy in Phase I human studies.